Special Issue "Prevention and Clinical Treatment of Alzheimer's Disease"

A special issue of Healthcare (ISSN 2227-9032).

Deadline for manuscript submissions: 25 February 2021.

Special Issue Editor

Dr. Syed Haris Omar
Website
Guest Editor
Rural Clinical School, Faculty of Medicine, University of New South Wales, Wagga Wagga, NSW 2650, Australia
Interests: Alzheimer's disease; Dementia; Amyloid; Tau; Biomarkers; Small molecules; Natural products; Biophenols; Mediterranean diet
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues, 

Alzheimer’s disease (AD) is a multifactorial disease in the elderly population, spreading at the global level, without specific treatment and cure. Clinically, AD is the most common form of dementia (50–70% of dementia cases), followed by vascular dementia (15–20%). Three decades ago, the involvement of amyloid beta (Aβ) and tau peptides in the pathophysiological mechanism of AD was put forward through the amyloid hypothesis. Lately, this theory has been criticised and challenged based on molecular studies. However, most of the neuronal damage in AD patients is due to these specific proteins which drive AD symptoms, including memory loss, behavioural changes, and cognitive issues. Mounting evidence suggests that free radicals, oxidative stress, pro-inflammatory cytokines and neurotoxic agents are directly or indirectly involved in the pathogenesis of AD. Currently, AD diagnosis is based on the determination of Aβ and tau levels in patients’ cerebrospinal fluid in combination with mental status assessment and neuroimaging. The investigation of new biomarkers is in its preliminary stage, and extensive trials are required to confirm their diagnostic validity in AD patients. As of now, there are no specific treatment and cure for AD. The search for molecules with less adverse effects than the available drugs has led researchers to investigate novel low-molecular-weight hybrid compounds of either synthetic or natural origin. Extensive research has been focused on natural products. In particular, biophenols have shown promising properties, being able to reduce AD pathogenesis in both in vitro and in vivo models.

Despite these advancements, a high rate of failure in drug trials on AD prevention and treatment has been observed, which is frustrating and causes delays in the development of new therapies for AD. Lifestyle changes, including dietary modification (adopting the Mediterranean diet or the MIND diet) and mild to moderate exercise, have shown promising results in the elderly population, including AD patients. In short, future drug candidates should be designed keeping in mind several aspects that are essential for their efficacy: ability to cross the blood–brain barrier, high bioavailability, and few side effects. This Special Issue, invites manuscripts (research, review, opinion and case studies) improving the current understanding, clinical prevention and treatment perspective of AD through the investigation of new biomarkers, the properties of Aβ and tau peptides, the role of enzymes and genetic mutations.

Dr. Syed Haris Omar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • Dementia
  • Amyloid and tau peptide
  • Biomarkers
  • Cerebraspinal Fluids
  • Neuroimaging
  • Mediterranean diet
  • Natural products
  • Prevention

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
A Robust Discriminant Framework Based on Functional Biomarkers of EEG and Its Potential for Diagnosis of Alzheimer’s Disease
Healthcare 2020, 8(4), 476; https://doi.org/10.3390/healthcare8040476 - 11 Nov 2020
Cited by 1
Abstract
(1) Background: Growing evidence suggests that electroencephalography (EEG), recording the brain’s electrical activity, can be a promising diagnostic tool for Alzheimer’s disease (AD). The diagnostic biomarkers based on quantitative EEG (qEEG) have been extensively explored, but few of them helped clinicians in their [...] Read more.
(1) Background: Growing evidence suggests that electroencephalography (EEG), recording the brain’s electrical activity, can be a promising diagnostic tool for Alzheimer’s disease (AD). The diagnostic biomarkers based on quantitative EEG (qEEG) have been extensively explored, but few of them helped clinicians in their everyday practice, and reliable qEEG markers are still lacking. The study aims to find robust EEG biomarkers and propose a systematic discrimination framework based on signal processing and computer-aided techniques to distinguish AD patients from normal elderly controls (NC). (2) Methods: In the proposed study, EEG signals were preprocessed firstly and Maximal overlap discrete wavelet transform (MODWT) was applied to the preprocessed signals. Variance, Pearson correlation coefficient, interquartile range, Hoeffding’s D measure, and Permutation entropy were extracted as the input of the candidate classifiers. The AD vs. NC discriminant performance of each model was evaluated and an automatic diagnostic framework was eventually developed. (3) Results: A classification procedure based on the extracted EEG features and linear discriminant analysis based classifier achieved the accuracy of 93.18 ± 3.65 (%), the AUC of 97.92 ± 1.66 (%), the F-measure of 94.06 ± 4.04 (%), separately. (4) Conclusions: The developed discrimination framework can identify AD from NC with high performance in a systematic routine. Full article
(This article belongs to the Special Issue Prevention and Clinical Treatment of Alzheimer's Disease)
Show Figures

Figure 1

Back to TopTop